Fanconi Syndrome

Comprehensive Pediatric Nephrology

Volumn , Issue , 2008, Pages 433-449

  Böckenhauer, Detlef ^a   Hoff, William G van't ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649666330     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04883-5.50034-9     Document Type: Chapter

References (283)

1. Fanconi G Die nicht diabetischen Glykosurien und Hyperglyklaemien des aelteren Kindes. Jahrbuch fuer Kinderheilkunde 1931, 133:257-300.
2. Lucas RC On a form of late rickets associated with albuminuria, rickets of adolescence. Lancet 1883, 993-994.
3. de Toni G Remarks on the relationship between renal rickets (renal dwarfism) and renal diabetes. Acta Pediatr 1933, 16:479-484.
4. Debre R, Marie J, et al. Rachitisme tardif coexistant avec une Nephrite chronique et une Glycosurie. Arch Med Enfants 1934, 37:597-606.
5. Fanconi G Der nephrotisch-glykosurische Zwergwuchs mit hypophosphataemischer Rachitis. Deutsche Medizinische Wochenschrift 1936, 62:1169-1171.
6. Norden AG, Scheinman SJ, et al. Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases. Kidney Int 2000, 57(1):240-249.
7. Laube GH, Russell-Eggitt IM, et al. Early proximal tubular dysfunction in Lowe's syndrome. Arch Dis Child 2004, 89(5):479-480.
8. Norden AG, Lapsley M, et al. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int 2001, 60(5):1885-1892.
9. Mogensen CE, Solling K Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. ScandJ Clin Lab Invest 1977, 37(6):477-486.
10. Birn H, Christensen EI Renal albumin absorption in physiology and pathology. Kidney Int 2006, 69(3):440-449.
11. Bazzi C, Petrini C, et al. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 2000, 58(4):1732-1741.
12. Valles P, Peralta M, et al. Follow-up of steroid-resistant nephrotic syndrome: tubular proteinuria and enzymuria. Pediatr Nephrol 2000, 15(3-4):252-258.
13. Houston IB, Boichis H, et al. Fanconi syndrome with renal sodium wasting and metabolic alkalosis. Am J Med 1968, 44(4):638-646.
14. Lemire J, Kaplan BS The various renal manifestations of the nephropathic form of cystinosis. Am J Nephrol 1984, 4(2):81-85.
15. Yildiz B, Durmus-Aydogdu S, et al. A patient with cystinosis presenting transient features of Bartter syndrome. Turk J Pediatr 2006, 48(3):260-262.
16. Rossi R, Godde A, et al. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995, 17(5):551-557.
17. Gahl WA, Bernardini IM, et al. Muscle carnitine repletion by long-term carnitine supplementation in nephropathic cystinosis. Pediatr Res 1993, 34(2):115-119.
18. Nissenkorn A, Korman SH, et al. Carnitine-deficient myopathy as a presentation of tyrosinemia type I. J Child Neurol 2001, 16(9):642-644.
19. Moestrup SK, Verroust PJ Megalin- and cubilin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia. Annu Rev Nutr 2001, 21:407-428.
20. Foreman JW, Bowring MA, et al. Effect of cystine dimethylester on renal solute handling and isolated renal tubule transport in the rat: a newmodel of the Fanconi syndrome. Metabolism 1987, 36(12):1185-1191.
21. Foreman JW, Benson L Effect of cystine loading and cystine dimethylester on renal brushborder membrane transport. Biosci Rep 1990, 10(5):455-459.
22. Salmon RF, Baum M Intracellular cystine loading inhibits transport in the rabbit proximal convoluted tubule. J Clin Invest 1990, 85(2):340-344.
23. Coor C, Salmon RF, et al. Role of adenosine triphosphate (ATP) and NaK ATPase in the inhibition of proximal tubule transport with intracellular cystine loading. J Clin Invest 1991, 87(3):955-961.
24. Bajaj G, Baum M Proximal tubule dysfunction in cystine-loaded tubules: effect of phosphate and metabolic substrates. Am J Physiol 1996, 271(3 Pt 2):F717-F722.
25. Sakarcan A, Aricheta R, et al. Intracellular cystine loading causes proximal tubule respiratory dysfunction: effect of glycine. Pediatr Res 1992, 32(6):710-713.
26. Foreman JW, Benson LL, et al. Metabolic studies of rat renal tubule cells loaded with cystine: the cystine dimethylester model of cystinosis. J Am Soc Nephrol 1995, 6(2):269-272.
27. Spencer PD, Medow MS, et al. Effects of succinylacetone on the uptake of sugars and amino acids by brush border vesicles. Kidney Int 1988, 34(5):671-677.
28. Wyss PA, Boynton SB, et al. Physiological basis for an animal model of the renal Fanconi syndrome: use of succinylacetone in the rat. ClinSci (Lond) 1992, 83(1):81-87.
29. Roth KS, Carter GE, et al. Succinylacetone effects on renal tubular phosphate metabolism: a model for experimental renal Fanconi syndrome. Proc Soc Exp Biol Med 1991, 196(4):428-431.
30. Eiam-ong S, Spohn M, et al. Insights into the biochemical mechanism of maleic acid-induced Fanconi syndrome. Kidney Int 1995, 48(5):1542-1548.
31. Levtchenko EN, Wilmer MJ, et al. Decreased intracellular ATP content and intact mitochondrial energy generating capacity in human cystinotic fibroblasts. Pediatr Res 2006, 59(2):287-292.
32. Laube GF, Shah V, et al. Glutathione depletion and increased apoptosis rate in human cystinotic proximal tubular cells. Pediatr Nephrol 2006, 21(4):503-509.
33. Lehrer-Graiwer JE, Firestein BL, et al. Nitric oxide mediated induction of cytochrome c oxidase mRNA and protein in a mouse macrophage cell line. Neurosci Lett 2000, 288(2):107-110.
34. Vasquez OL, Almeida A, et al. Depletion of glutathione up-regulates mitochondrial complex I expression in glial cells. J Neurochem 2001, 76(5):1593-1596.
35. Brealey D, Brand M, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002, 360(9328):219-223.
36. Gegg ME, Beltran B, et al. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration?. J Neurochem 2003, 86(1):228-237.
37. Rizzo C, Ribes A, et al. Pyroglutamic aciduria and nephropathic cystinosis. J Inherit Metab Dis 1999, 22(3):224-226.
38. Mannucci L, Pastore A, et al. Impaired activity of the gammaglutamyl cycle in nephropathic cystinosis fibroblasts. Pediatr Res 2006, 59(2):332-335.
39. Chol M, Nevo N, et al. Glutathione precursors replenish decreased glutathione pool in cystinotic cell lines. Biochem Biophys Res Commun 2004, 324(1):231-235.
40. Butler JD, Key JD, et al. Glutathione metabolism in normal and cystinotic fibroblasts. Exp Cell Res 1987, 172(1):158-167.
41. Levtchenko E, de Graaf-Hess A, et al. Altered status of glutathione and its metabolites in cystinotic cells. Nephrol Dial Transplant 2005, 20(9):1828-1832.
42. Wilmer MJ, de Graaf-Hess A, et al. Elevated oxidized glutathione in cystinotic proximal tubular epithelial cells. Biochem Biophys Res Commun 2005, 337(2):610-614.
43. Rossi R, Kleta R, et al. Renal involvement in children with malignancies. Pediatr Nephrol 1999, 13(2):153-162.
44. Sener G, Sehirli O, et al. Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats. J Pineal Res 2004, 37(1):17-25.
45. Schwerdt G, Freudinger R, et al. The nephrotoxin ochratoxin A induces apoptosis in cultured human proximal tubule cells. Cell Biol Toxicol 1999, 15(6):405-415.
46. Haviv YS, Wald H, et al. Late-onset downregulation of NaPi-2 in experimental Fanconi syndrome. Pediatr Nephrol 2001, 16(5):412-416.
47. Cetinkaya I, Schlatter E, et al. Inhibition of Na(+)-dependent transporters in cystine-loaded human renal cells: electrophysiological studies on the Fanconi syndrome of cystinosis. J Am Soc Nephrol 2002, 13(8):2085-2093.
48. Pontoglio M, Barra J, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996, 84(4):575-585.
49. Cheret C, Doyen A, et al. Hepatocyte nuclear factor 1 alpha controls renal expression of the Npt1-Npt4 anionic transporter locus. J Mol Biol 2002, 322(5):929-941.
50. Verroust PJ, Birn H, et al. The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. Kidney Int 2002, 62(3):745-756.
51. Vormann J Magnesium: nutrition and metabolism. Mol Aspects Med 2003, 24(1-3):27-37.
52. Christensen EI, Gburek J Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology. Pediatr Nephrol 2004, 19(7):714-721.
53. Hilpert J, Nykjaer A, et al. Megalin antagonizes activation of the parathyroid hormone receptor. J Biol Chem 1999, 274(9):5620-5625.
54. Nykjaer A, Dragun D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96(4):507-515.
55. Nykjaer A, Fyfe JC, et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A 2001, 98(24):13895-13900.
56. Raychowdhury R, Niles JL, et al. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science 1989, 244(4909):1163-1165.
57. Christensen EI, Birn H Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002, 3(4):256-266.
58. Leheste JR, Rolinski B, et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999, 155(4):1361-1370.
59. Moestrup SK, Kozyraki R, et al. The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J Biol Chem 1998, 273(9):5235-5242.
60. Grasbeck R, Gordin R, et al. Selective vitamin B12 malabsorption and proteinuria in young people. A syndrome. Acta Med Scand 1960, 167:289-296.
61. Imerslund O Idiopathic chronic megaloblastic anemia in children. Acta Paediatr Suppl 1960, 49(Suppl 119):1-115.
62. Wahlstedt-Froberg V, Pettersson T, et al. Proteinuria in cubilin-deficient patients with selective vitamin B12 malabsorption. Pediatr Nephrol 2003, 18(5):417-421.
63. Norden AG, Lapsley M, et al. Urinary megalin deficiency implicates abnormal tubular endocytic function in Fanconi syndrome. J Am Soc Nephrol 2002, 13(1):125-133.
64. Christensen EI, Devuyst O, et al. Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci US A 2003, 100(14):8472-8477.
65. Endo F, Sun MS Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells. J Inherit Metab Dis 2002, 25(3):227-234.
66. Thevenod F, Friedmann JM Cadmium-mediated oxidative stress in kidney proximal tubule cells induces degradation of Na+/K (+)-ATPase through proteasomal and endo-/lysosomal proteolytic pathways. FASEB J 1999, 13(13):1751-1761.
67. Park MA, Thoene JG Potential role of apoptosis in development of the cystinotic phenotype. Pediatr Nephrol 2005, 20(4):441-446.
68. Park MA, Pejovic V, et al. Increased apoptosis in cystinotic fibroblasts and renal proximal tubule epithelial cells results from cyste-inylation of protein kinase Cdelta. J Am Soc Nephrol 2006, 17(11):3167-3175.
69. Gahl WA, Bashan N, et al. Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science 1982, 217(4566):1263-1265.
70. Gahl W, Thoene J, et al. Cystinosis: a disorder of lysosomal membrane transport. The metabolic and molecular basis of inherited disease 2001, 5085-5108. McGraw-Hill, New York. C.R. Scriver, A. Beaudet, D. Valle, W. Sly (Eds.).
71. Gahl WA, Theone JG, et al. Cystinosis. N Engl J Med 2002, 347(2):111-121.
72. Linkage of the gene for cystinosis to markers on the short arm of chromosome 17. Nat Genet 1995, 10(2):246-248. The Cystinosis Collaborative Research Group.
73. Town M, Jean G, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 1998, 18(4):319-324.
74. Haq MR, Kalatzis V, et al. Immunolocalization of cystinosin, the protein defective in cystinosis. J Am Soc Nephrol 2002, 13(8):2046-2051.
75. Cherqui S, Kalatzis V, et al. The targeting of cystinosin to the lysosomal membrane requires a tyrosine-based signal and a novel sorting motif. J Biol Chem 2001, 276(16):13314-13321.
76. Kalatzis V, Cherqui S, et al. Cystinosin, the protein defective in cystinosis, is a H (+)-driven lysosomal cystine transporter. EMBO J 2001, 20(21):5940-5949.
77. Forestier L, Jean G, et al. Molecular characterization of CTNS deletions in nephropathic cystinosis: development of a PCR-based detection assay. Am J Hum Genet 1999, 65(2):353-359.
78. Kalatzis V, Antignac C New aspects of the pathogenesis of cystinosis. Pediatr Nephrol 2003, 18(3):207-215.
79. Attard M, Jean G, et al. Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin. Hum Mol Genet 1999, 8(13):2507-2514.
80. Collin S, van't Hoff W UK Cystinosis Registry (in Abstracts of the 3rd International Cystinosis Conference). J Inherit Metab Dis 2005, 28:1211-1212.
81. Steinherz R, Chesney RW, et al. Circulating vitamin D metabolites in nephropathic cystinosis. J Pediatr 1983, 102(4):592-594.
82. Wong V The eye and cystinosis. Cystinosis 1972, 23-35. U.S. Department of Health, Education and Welfare (NIH 72-249), Washington, DC. J.D. Schulman (Ed.).
83. Gahl WA, Kuehl EM, et al. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab 2000, 71(1-2):100-120.
84. Patrick AD, Lake BD Cystinosis: electron microscopic evidence of lysosomal storage of cystine in lymph node. J Clin Pathol 1968, 21(5):571-575.
85. Schneider JA, Wong V, et al. The early diagnosis of cystinosis. J Pediatr 1969, 74(1):114-116.
86. Jackson M, Young E Prenatal diagnosis of cystinosis by quantitative measurement of cystine in chorionic villi and cultured cells. Prenat Diagn 2005, 25(11):1045-1047.
87. Smith ML, Clark KF, et al. Diagnosis of cystinosis with use of placenta. N Engl J Med 1989, 321(6):397-398.
88. Gretz N, Manz F, et al. Survival time in cystinosis. A collaborative study. Proceedings of the European Dialysis and Transplant Association 1982, 19:582-589.
89. Schnaper HW, Cottel J, et al. Early occurrence of end-stage renal disease in a patient with infantile nephropathic cystinosis. J Pediatr 1992, 120(4 Pt 1):575-578.
90. van't Hoff WG, Gretz N The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire. Pediatr Nephrol 1995, 9(6):685-689.
91. Gubler MC, Lacoste M, et al. The pathology of the kidney in cystinosis. Cystinosis 1999, 42-48. Elsevier, Paris. M. Broyer (Ed.).
92. Spear GS The pathology of the kidney. Cystinosis 1972, 37-53. U.S. Department of Health, Education and Welfare (NIH 72-249), Washington, DC. J.D. Schulman (Ed.).
93. Spear GS, Gubler MC, et al. Dark cells of cystinosis: occurrence in renal allografts. Hum Pathol 1989, 20(5):472-476.
94. Saleem MA, Milford DV, et al. Hypercalciuria and ultrasound abnormalities in children with cystinosis. Pediatr Nephrol 1995, 9(1):45-47.
95. Theodoropoulos DS, Shawker TH, et al. Medullary nephrocalcinosis in nephropathic cystinosis. Pediatr Nephrol 1995, 9(4):412-418.
96. Strife CF, Strife JL, et al. Acquired structural genitourinary abnormalities contributing to deterioration of renal function in older patients with nephropathic cystinosis. Pediatrics 1991, 88(6):1238-1241.
97. Broyer M, Tete MJ, et al. Late symptoms in infantile cystinosis. Pediatr Nephrol 1987, 1(3):519-524.
98. Ehrich JH, Loirat C, et al. Report on management of renal failure in children in Europe, XXII, 1991. Nephrol Dial Transplant 1992, 7(Suppl 2):36-48.
99. Wilson DP, Jelley D, et al. Nephropathic cystinosis: improved linear growth after treatment with recombinant human growth hormone. J Pediatr 1989, 115(5 Pt 1):758-761.
100. Wuhl E, Haffner D, et al. Treatment with recombinant human growth hormone in short children with nephropathic cystinosis: no evidence for increased deterioration rate of renal function. The European Study Group on Growth Hormone Treatment in Short Children with Nephropathic Cystinosis. Pediatr Res 1998, 43(4 Pt 1):484-488.
101. Wuhl E, Haffner D, et al. Long-term treatment with growth hormone in short children with nephropathic cystinosis. J Pediatr 2001, 138(6):880-887.
102. Chan AM, Lynch MJ, et al. Hypothyroidism in cystinosis. A clinical, endocrinologic and histologic study involving sixteen patients with cystinosis. Am J Med 1970, 48(6):678-692.
103. Burke JR, El-Bishti MM, et al. Hypothyroidism in children with cystinosis. Arch Dis Child 1978, 53(12):947-951.
104. Broyer M, Guillot M, et al. Infantile cystinosis: a reappraisal of early and late symptoms. Adv Nephrol Necker Hosp 1981, 10:137-166.
105. Gahl WA, Schneider JA, et al. Course of nephropathic cystinosis after age 10 years. J Pediatr 1986, 109(4):605-608.
106. Kimonis VE, Troendle J, et al. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 1995, 80(11):3257-3261.
107. Robert JJ, Tete MJ, et al. Impaired insulin tolerance and insulin-dependent diabetes mellitus in infantile nephropathic cystinosis. Cystinosis 1999, 56-62. Elsevier, Paris. M. Broyer (Ed.).
108. Fivush B, Green OC, et al. Pancreatic endocrine insufficiency in posttransplant cystinosis. Am J Dis Child 1987, 141(10):1087-1089.
109. Milner RD, Wirdnam PK The pancreatic beta cell fraction in children with errors of amino acid metabolism. Pediatr Res 1982, 16(3):213-216.
110. Gahl WA, Kaiser-Kupfer MI Complications of nephropathic cystinosis after renal failure. Pediatr Nephrol 1987, 1(3):260-268.
111. Winkler L, Offner G, et al. Growth and pubertal development in nephropathic cystinosis. Eur J Pediatr 1993, 152(3):244-249.
112. Reiss RE, Kuwabara T, et al. Successful pregnancy despite placental cystine crystals in a woman with nephropathic cystinosis. N Engl J Med 1988, 319(4):223-226.
113. Andrews PA, Sacks SH, et al. Successful pregnancy in cystinosis. JAMA 1994, 272(17):1327-1328.
114. Fink JK, Brouwers P, et al. Neurologic complications in longstanding nephropathic cystinosis. Arch Neurol 1989, 46(5):543-548.
115. Vogel DG, Malekzadeh MH, et al. Central nervous system involvement in nephropathic cystinosis. J Neuropathol Exp Neurol 1990, 49(6):591-599.
116. Gahl WA, Dalakas MC, et al. Myopathy and cystine storage in muscles in a patient with nephropathic cystinosis. N Engl J Med 1988, 319(22):1461-1464.
117. Anikster Y, Lacbawan F, et al. Pulmonary dysfunction in adults with nephropathic cystinosis. Chest 2001, 119(2):394-401.
118. Van Lierde A, Colombo D, et al. Hemiparesis in a girl with cystinosis and renal transplant. Eur J Pediatr 1994, 153(9):702-703.
119. Broyer M, Tete MJ Central nervous system complications in cystinosis. Cystinosis 1999, 75-80. Elsevier, Paris. M. Broyer (Ed.).
120. Dogulu CF, Tsilou E, et al. Idiopathic intracranial hypertension in cystinosis. J Pediatr 2004, 145(5):673-678.
121. Van Damme BJ, Fleuren GJ, et al. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 1978, 38(4):502-510.
122. Cochat P, Drachman PR, et al. Cerebral atrophy and nephropathic cystinosis. Arch Dis Child 1986, 61(4):401-403.
123. Fushimi K, Uchida S, et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1996, 361(6412):549-552.
124. Sonies BC, Ekman EF, et al. Swallowing dysfunction in nephropathic cystinosis. N Engl J Med 1990, 323(9):565-570.
125. Sonies BC, Almajid P, et al. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy. Medicine (Baltimore) 2005, 84(3):137-146.
126. Wolff G, Ehrich JH, Offner G, Brodehl J Psychosocial and intellectual development in 12 patients with infantile nephropathic cystinosis. Acta Scan Paediatr 1982, 71:1007-1011.
127. Trauner DA, Chase C, et al. Neurologic and cognitive deficits in children with cystinosis. J Pediatr 1988, 112(6):912-914.
128. Ballantyne AO, Trauner DA Neurobehavioral consequences of a genetic metabolic disorder: visual processing deficits in infantile nephropathic cystinosis. Neuropsychiatry Neuropsychol Behav Neurol 2000, 13(4):254-263.
129. Kaiser-Kupfer MI, Caruso RC, et al. Long-term ocular manifestations in nephropathic cystinosis. Arch Ophthalmol 1986, 104(5):706-711.
130. Tsilou ET, Rubin BI, et al. Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis. Cornea 2002, 21(2):173-176.
131. Schneider JA, Katz B, et al. Update on nephropathic cystinosis. Pediatr Nephrol 1990, 4(6):645-653.
132. Dohil R, Newbury RO, et al. The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 2003, 143(2):224-230.
133. Dohil R, Fidler M, et al. Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Pediatr Nephrol 2005, 20(12):1786-1793.
134. Gahl WA Cystinosis coming of age. Adv Pediatr 1986, 33:95-126.
135. Rossi S, Herrine SK, et al. Cystinosis as a cause of noncirrhotic portal hypertension. Dig Dis Sci 2005, 50(7):1372-1375.
136. O'Brien K, Hussain N, et al. Nodular regenerative hyperplasia and severe portal hypertension in cystinosis. Clin Gastroenterol Hepatol 2006, 4(3):387-394.
137. Strayer DS Cystinosis and dissecting aortic aneurysm in a 7-year-old boy. Am J Dis Child 1979, 133(4):436-438.
138. Olgar S, Nisli K, et al. Can cystinosis cause coronary artery dilatation?. Pediatr Cardiol 2006, 27(2):263-268.
139. Dixit MP, Greifer I Nephropathic cystinosis associated with car-diomyopathy: a 27-year clinical follow-up, BMC. Nephrol 2002, 3:8.
140. Ueda M, O'Brien K, et al. Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol 2006, 1:555-562.
141. Almond PS, Matas AJ, et al. Renal transplantation for infantile cystinosis: long-term follow-up. J Pediatr Surg 1993, 28(2):232-238.
142. Goldman H, Scriver CR, et al. Adolescent cystinosis: comparisons with infantile and adult forms. Pediatrics 1971, 47(6):979-988.
143. Langman CB, Moore ES, et al. Renal failure in a sibship with lateonset cystinosis. J Pediatr 1985, 107(5):755-756.
144. Gahl WM, Renlund M, et al. Disorders of lysosomal transport: cystinosis and sialic acid storage disorders. The metabolic basis of inherited disease 1989, 2619-2647. McGraw-Hill, New York. C.R. Scriver, A. Beaudet, W. Sly (Eds.).
145. Wrong OM, Norden AG, et al. Dent's disease: a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance, Q. J Med 1994, 87(8):473-493.
146. Dent CE, Friedman M Hypercalcuric rickets associated with renal tubular damage. Arch Dis Child 1964, 39:240-249.
147. Lloyd SE, Pearce SH, et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996, 379(6564):445-449.
148. Akuta N, Lloyd SE, et al. Mutations of CLCN5 in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis. Kidney Int 1997, 52(4):911-916.
149. Lloyd SE, Pearce SH, et al. Idiopathic low molecular weight proteinuria associated with hypercalciuric nephrocalcinosis in Japanese children is due to mutations of the renal chloride channel (CLCN5). J Clin Invest 1997, 99(5):967-974.
150. Langlois V, Bernard C, et al. Clinical features of X-linked nephrolithiasis in childhood. Pediatr Nephrol 1998, 12(8):625-629.
151. Igarashi T, Inatomi J, et al. Clinical and genetic studies of CLCN5 mutations in Japanese families with Dent's disease. Kidney Int 2000, 58(2):520-527.
152. Scheinman SJ, Cox JP, et al. Isolated hypercalciuria with mutation in CLCN5: relevance to idiopathic hypercalciuria. Kidney Int 2000, 57(1):232-239.
153. Thakker RV Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis. Kidney Int 2000, 57(3):787-793.
154. Hoopes RR, Hueber PA, et al. CLCN5 chloride-channel mutations in six new North American families with X-linked nephrolithiasis. Kidney Int 1998, 54(3):698-705.
155. Cebotaru V, Kaul S, et al. High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent's disease. Kidney Int 2005, 68(2):642-652.
156. Raja KA, Schurman S, et al. Responsiveness of hypercalciuria to thiazide in Dent's disease. J Am Soc Nephrol 2002, 13(12):2938-2944.
157. Nijenhuis T, Vallon V, et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005, 115(6):1651-1658.
158. Piwon N, Gunther W, et al. ClC-5 Cl-channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 2000, 408(6810):369-373.
159. Accardi A, Miller C Secondary active transport mediated by a prokaryotic homologue of ClC Cl-channels. Nature 2004, 427(6977):803-807.
160. Scheel OA, Zdebik AA, et al. Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 2005, 436(7049):424-427.
161. Wang Y, Cai H, et al. ClC-5: role in endocytosis in the proximal tubule. Am J Physiol Renal Physiol 2005, 289(4):F850-F862.
162. Hryciw DH, Ekberg J, et al. Regulation of albumin endocytosis by PSD95/Dlg/ZO-1 (PDZ) scaffolds. Interaction of Na+-H+ exchange regulatory factor-2 with ClC-5. J Biol Chem 2006, 281(23):16068-16077.
163. Hryciw DH, Ekberg J, et al: ClC-5 a chloride channel with multiple roles in renal tubular albumin uptake. Int J Biochem Cell Biol 38 (7): 1036-42.
164. Gunther W, Piwon N, et al. The ClC-5 chloride channel knock-out mouse-an animal model for Dent's disease. Pflugers Arch 2003, 445(4):456-462.
165. Silva IV, Cebotaru V, et al: The ClC-5 knockout mouse model of Dent's disease has renal hypercalciuria and increased bone turnover. J Bone Miner Res 18 (4): 615-23.
166. Devuyst O, Jouret F, et al. Chloride channels and endocytosis: new insights from Dent's disease and ClC-5 knockout mice. Nephron Physiol 2005, 99(3):69-73.
167. Hoopes RR, Shrimpton AE, et al. Dent disease with mutations in OCRL1. Am J Hum Genet 2005, 76(2):260-267.
168. Norden AG, Sharratt P, et al. Quantitative amino acid and proteomic analysis: very low excretion of polypeptides >750 Da in normal urine. Kidney Int 2004, 66(5):1994-2003.
169. Janne PA, Suchy SF, et al. Functional overlap between murine Inpp5b and Ocrl1 may explain why deficiency of the murine ortholog for OCRL1 does not cause Lowe syndrome in mice. J Clin Invest 1998, 101(10):2042-2053.
170. Utsch B, Bokenkamp A, Benz MR, Besbas N, et al. Novel OCRL1 mutations in patients with the phenotype of Dent disease. Am J Kidney Dis 2006, 48(6):942-956.
171. Lowe CU, Terrey M, et al. Organic-aciduria, decreased renal ammonia production, hydrophthalmos, and mental retardation: a clinical entity. AMA Am J Dis Child 1952, 83(2):164-184.
172. Abbassi V, Lowe CU, et al. Oculo-cerebro-renal syndrome. A review. Am J Dis Child 1968, 115(2):145-168.
173. Charnas LR, Bernardini I, et al. Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med 1991, 324(19):1318-1325.
174. Witzleben CL, Schoen EJ, et al. Progressive morphologic renal changes in the oculo-cerebro-renal syndrome of Lowe. Am J Med 1968, 44(2):319-324.
175. Tricot L, Yahiaoui Y, et al. End-stage renal failure in Lowe syndrome. Nephrol Dial Transplant 2003, 18(9):1923-1925.
176. Schramm L, Gal A, et al. Advanced renal insufficiency in a 34-year-old man with Lowe syndrome. Am J Kidney Dis 2004, 43(3):538-543.
177. Scholten HG Een meisje met Lowe-syndrome. Maandschrift voor Kindergeneeskunde 1960, 28:251-255.
178. Reilly DS, Lewis RA, et al. Tightly linked flanking markers for the Lowe oculocerebrorenal syndrome, with application to carrier assessment. Am J Hum Genet 1988, 42(5):748-755.
179. Brown N, Gardner RJ Lowe syndrome: identification of the carrier state. Birth Defects 1976, 12(3):579-595.
180. Delleman JW, Bleeker-Wagemakers EM, et al. Opacities of the lens indicating carrier status in the oculo-cerebro-renal (Lowe) syndrome. J Pediatr Ophthalmol 1977, 14(4):205-212.
181. Cibis GW, Waeltermann JM, et al. Lenticular opacities in carriers of Lowe's syndrome. Ophthalmology 1986, 93(8):1041-1045.
182. Lin T, Lewis RA, et al. Molecular confirmation of carriers for Lowe syndrome. Ophthalmology 1999, 106(1):119-122.
183. Roschinger W, Muntau AC, et al. Carrier assessment in families with lowe oculocerebrorenal syndrome: novel mutations in the OCRL1 gene and correlation of direct DNA diagnosis with ocular examination. Mol Genet Metab 2000, 69(3):213-222.
184. Lin T, Orrison BM, et al. Spectrum of mutations in the OCRL1 gene in the Lowe oculocerebrorenal syndrome. Am J Hum Genet 1997, 60(6):1384-1388.
185. Lin T, Orrison BM, et al. Mutations are not uniformly distributed throughout the OCRL1 gene in Lowe syndrome patients. Mol Genet Metab 1998, 64(1):58-61.
186. Monnier N, Satre V, et al. OCRL1 mutation analysis in French Lowe syndrome patients: implications for molecular diagnosis strategy and genetic counseling. Hum Mutat 2000, 16(2):157-165.
187. Attree O, Olivos IM, et al. The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature 1992, 358(6383):239-242.
188. Olivos-Glander IM, Janne PA, et al. The oculocerebrorenal syndrome gene product is a 105-kD protein localized to the Golgi complex. Am J Hum Genet 1995, 57(4):817-823.
189. Dressman MA, Olivos-Glander IM, et al. Ocrl1, a PtdIns(4, 5)P(2) 5-phosphatase, is localized to the trans-Golgi network of fibroblasts and epithelial cells. J Histochem Cytochem 2000, 48(2):179-190.
190. Ungewickell A, Ward ME, et al. The inositol polyphosphate 5-phosphatase Ocrl associates with endosomes that are partially coated with clathrin. Proc Natl Acad Sci USA 2004, 101(37):13501-13506.
191. Choudhury R, Diao A, et al. Lowe syndrome protein OCRL1 interacts with clathrin and regulates protein trafficking between endosomes and the trans-Golgi network. Mol Biol Cell 2005, 16(8):3467-3479.
192. Toker A The synthesis and cellular roles of phosphatidylinositol 4, 5-bisphosphate. Curr Opin Cell Biol 1998, 10(2):254-261.
193. Raucher D, Stauffer T, et al. Phosphatidylinositol 4, 5-bisphosphate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion. Cell 2000, 100(2):221-228.
194. Zhang X, Hartz PA, et al. Cell lines from kidney proximal tubules of a patient with Lowe syndrome lack OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4, 5-bisphosphate. J Biol Chem 1998, 273(3):1574-1582.
195. Suchy SF, Nussbaum RL The deficiency of PIP2 5-phosphatase in Lowe syndrome affects actin polymerization. Am J Hum Genet 2002, 71(6):1420-1427.
196. Sassa S, Kappas A: Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 71 (3): 625-34.
197. Holme E, Lindstedt S Tyrosinaemia type I and NTBC(2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione). J Inherit Metab Dis 1998, 21(5):507-517.
198. McKiernan PJ Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006, 66(6):743-750.
199. Tuchman M, Freese DK, et al. Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation. J Pediatr 1987, 110(3):399-403.
200. Pierik LJ, van Spronsen FJ, et al. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up. J Inherit Metab Dis 2005, 28(6):871-876.
201. Niaudet P, Rotig A Renal involvement in mitochondrial cytopathies. Pediatr Nephrol 1996, 10(3):368-373.
202. Thorner PS, Balfe JW, et al. Abnormal mitochondria on a renal biopsy from a case of mitochondrial myopathy. Pediatr Pathol 1985, 4(1-2):25-35.
203. Santer R, Schneppenheim R, et al. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet 1997, 17(3):324-326.
204. Santer R, Schneppenheim R, et al. Fanconi-Bickel syndrome-the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Eur J Pediatr 1998, 157(10):783-797.
205. Guillam MT, Hummler E, et al. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet 1997, 17(3):327-330.
206. Brivet M, Moatti N, et al. Defective galactose oxidation in a patient with glycogen storage disease and Fanconi syndrome. Pediatr Res 1983, 17(2):157-161.
207. Odievre MH, Lombes A, et al. A secondary respiratory chain defect in a patient with Fanconi-Bickel syndrome. J Inherit Metab Dis 2002, 25(5):379-384.
208. Sakamoto O, Ogawa E, et al. Mutation analysis of the GLUT2 gene in patients with Fanconi-Bickel syndrome. Pediatr Res 2000, 48(5):586-589.
209. Santer R, Steinmann B, et al. Fanconi-Bickel syndrome-a congenital defect of facilitative glucose transport. Curr Mol Med 2002, 2(2):213-227.
210. Santer R, Kinner M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003, 14(11):2873-2882.
211. Francis J, Zhang J, et al. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 2004, 19(11):2893-2895.
212. Lee PJ, van't Hoff WG, et al. Catch-up growth in Fanconi-Bickel syndrome with uncooked cornstarch. J Inherit Metab Dis 1995, 18(2):153-156.
213. Morris RC, Nigon K, et al. Evidence that the severity of depletion of inorganic phosphate determines the severity of the disturbance of adenine nucleotide metabolism in the liver and renal cortex of the fructose-loaded rat. J Clin Invest 1978, 61(1):209-220.
214. Lu M, Holliday LS, et al. Interaction between aldolase and vacuolar H+-ATPase: evidence for direct coupling of glycolysis to the ATP-hydrolyzing proton pump. J Biol Chem 2001, 276(32):30407-30413.
215. Goldberg L, Holzel A, et al: A clinical and biochemical study of galactosaemiaa possible explanation of the nature of the biochemical lesion Arch Dis Child 31 (158): 254-64.
216. Gissen P, Johnson CA, et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogry posis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet 2004, 36(4):400-404.
217. Eastham KM, McKiernan PJ, et al. ARC syndrome: an expanding range of phenotypes. Arch Dis Child 2001, 85(5):415-420.
218. Horslen SP, Quarrell OW, et al. Liver histology in the arthrogryposis multiplex congenita, renal dysfunction, and cholestasis (ARC) syndrome: report of three new cases and review. J Med Genet 1994, 31(1):62-64.
219. Di Rocco M, Callea F, et al. Arthrogryposis, renal dysfunction and cholestasis syndrome: report of five patients from three Italian families. Eur J Pediatr 1995, 154(10):835-839.
220. Gissen P, Tee L, et al. Clinical and molecular genetic features of ARC syndrome. Hum Genet 2006, 120(3):396-409.
221. Levy M, Gagnadoux MF, et al. Membranous glomerulonephritis associated with anti-tubular and anti-alveolar basement membrane antibodies. Clin Nephrol 1978, 10(4):158-165.
222. Dumas R, Dumas ML, et al. [Membranous glomerulonephritis in two brothers associated in one with tubulo-interstitial disease, Fanconi syndrome and anti-TBM antibodies]. Arch Fr Pediatr 1982, 39(2):75-78.
223. Wood EG, Brouhard BH, et al. Membranous glomerulonephropathy with tubular dysfunction and linear tubular basement membrane IgG deposition. J Pediatr 1982, 101(3):414-417.
224. Yagame M, Tomino Y, et al. An adult case of Fanconi's syndrome associated with membranous nephropathy. Tokai J Exp Clin Med 1986, 11(2):101-106.
225. Katz A, Fish AJ, et al. Role of antibodies to tubulointerstitial nephritis antigen in human anti-tubular basement membrane nephritis associated with membranous nephropathy. Am J Med 1992, 93(6):691-698.
226. Makker SP, Widstrom R, et al. Membranous nephropathy, interstitial nephritis, and Fanconi syndrome-glomerular antigen. Pediatr Nephrol 1996, 10(1):7-13.
227. Griswold WR, Krous HF, et al. The syndrome of autoimmune interstitial nephritis and membranous nephropathy. Pediatr Nephrol 1997, 11(6):699-702.
228. Tay AH, Ren EC, et al. Membranous nephropathy with anti-tubular basement membrane antibody may be X-linked. Pediatr Nephrol 2000, 14(8-9):747-753.
229. Kazama I, Matsubara M, et al. Adult onset Fanconi syndrome: extensive tubulo-interstitial lesions and glomerulopathy in the early stage of Chinese herbs nephropathy. Clin Exp Nephrol 2004, 8(3):283-287.
230. Shenoy M, Krishnan R, et al. Childhood membranous nephropathy in association with interstitial nephritis and Fanconi syndrome. Pediatr Nephrol 2006, 21(3):441.
231. Rossi R, Ehrich JH Partial and complete de Toni-Debre-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy. Eur J Clin Pharmacol 1993, 44(Suppl 1):S43-S45.
232. Skinner R, Pearson AD, et al. Risk factors for ifosfamide nephro-toxicity in children. Lancet 1996, 348(9027):578-580.
233. Loebstein R, Koren G Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics 1998, 101(6):E8.
234. Skinner R, Pearson AD, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 1998, 77(10):1677-1682.
235. Rossi R, Pleyer J, et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol 1999, 32(3):177-182.
236. Loebstein R, Atanackovic G, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999, 39(5):454-461.
237. Skinner R, Cotterill SJ, et al. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000, 82(10):1636-1645.
238. Macpherson NA, Moscarello MA, et al. Aminoaciduria is an earlier index of renal tubular damage than conventional renal disease markers in the gentamicin-rat model of acute renal failure. Clin Invest Med 1991, 14(2):101-110.
239. Izzedine H, Launay-Vacher V, et al. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003, 41(2):292-309.
240. Haffner D, Weinfurth A, et al. Body growth in primary de Toni-Debre-Fanconi syndrome. Pediatr Nephrol 1997, 11(1):40-45.
241. Neimann N, Pierson M, et al. [Familial glomerulo-tubular nephropathy with the de Toni-Debre-Fanconi syndrome]. Arch Fr Pediatr 1968, 25(1):43-69.
242. Friedman AL, Trygstad CW, et al. Autosomal dominant Fanconi syndrome with early renal failure. Am J Med Genet 1978, 2(3):225-232.
243. Patrick A, Cameron JS, et al. A family with a dominant form of idiopathic Fanconi syndrome leading to renal failure in adult life. ClinNephrol 1981, 16(6):289-292.
244. Tieder M, Arie R, et al. Elevated serum 1, 25-dihydroxyvitamin D concentrations in siblings with primary Fanconi's syndrome. N Engl J Med 1988, 319(13):845-849.
245. Wen SF, Friedman AL, et al. Two case studies from a family with primary Fanconi syndrome. Am J Kidney Dis 1989, 13(3):240-246.
246. Tolaymat A, Sakarcan A, et al. Idiopathic Fanconi syndrome in a family. Part I. Clinical aspects. J Am Soc Nephrol 1992, 2(8):1310-1317.
247. Frisch LS, Mimouni F Hypomagnesemia following correction of metabolic acidosis: a case of hungry bones. J Am Coll Nutr 1993, 12(6):710-713.
248. Haycock GB, Al-Dahhan J, et al. Effect of indomethacin on clinical progress and renal function in cystinosis. Arch Dis Child 1982, 57(12):934-939.
249. Clark KF A comparative study of indomethacin for the treatment of the Fanconi syndrome in cystinosis. J Rare Dis 1996, 11:5-12.
250. Callis L, Castello F, et al. Studies on the site of renal sodium loss in two patients with cystinosis. Effects of hydrochlorothiazide on tubular sodium reabsorptive mechanisms. Nephron 1977, 18(1):35-40.
251. Pisoni RL, Thoene JG, et al. Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. Role in therapeutic cystine removal?. J Biol Chem 1985, 260(8):4791-4798.
252. Gahl WA, Reed GF, et al. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 1987, 316(16):971-977.
253. Markello TC, Bernardini IM, et al. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 1993, 328(16):1157-1162.
254. Kleta R, Bernardini I, et al. Long-term follow-up of well-treated nephropathic cystinosis patients. J Pediatr 2004, 145(4):555-560.
255. Broyer M [Cystinosis from childhood to adulthood]. Nephrologie 2000, 21(1):13-18.
256. Gahl WA Early oral cysteamine therapy for nephropathic cystinosis. EurJ Pediatr 2003, 162(Suppl 1):S38-S41.
257. Kaiser-Kupfer MI, Gazzo MA, et al. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis. Arch Ophthalmol 1990, 108(5):689-693.
258. Iwata F, Kuehl EM, et al. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis. Mol Genet Metab 1998, 64(4):237-242.
259. Tsilou ET, Thompson D, et al. A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br J Ophthalmol 2003, 87(1):28-31.
260. Belldina EB, Huang MY, et al: Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients Br J Clin Pharmacol 56 (5): 520-25.
261. Levtchenko EN, van Dael CM, et al. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol 2006, 21(1):110-113.
262. Sadoff L Nephrotoxicity of streptozotocin (NSC-85998). Cancer Chemother Rep 1970, 54(6):457-459.
263. Kintzel PE Anticancer drug-induced kidney disorders. Drug Saf 2001, 24(1):19-38.
264. Montoliu J, Carrera M, et al. Lactic acidosis and Fanconi's syndrome due to degraded tetracycline. BMJ (Clin Res Ed) 1981, 283(6306):1576-1577.
265. Cleveland WW, Adams WC, et al. Acquired Fanconi syndrome following degraded tetracycline. J Pediatr 1965, 66:333-342.
266. Vittecoq D, Dumitrescu L, et al. Fanconi syndrome associated with cidofovir therapy. Antimicrob Agents Chemother 1997, 41(8):1846.
267. Verhelst D, Monge M, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002, 40(6):1331-1333.
268. Earle KE, Seneviratne T, et al. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004, 19(5):714-721.
269. Izzedine H, Hulot JS, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006, 194(11):1481-1491.
270. Crowther MA, Callaghan W, et al. Dideoxyinosine-associated nephrotoxicity. AIDS 1993, 7(1):131-132.
271. Izzedine H, Launay-Vacher V, et al. Fanconi syndrome associated with didanosine therapy. AIDS 2005, 19(8):844-845.
272. Chisolm JJ, Harrison HC, et al. Amino-aciduria, hypophospha-temia, and rickets in lead poisoning: study of a case. AMA Am J Dis Child 1955, 89(2):159-168.
273. Kazantzis G, Flynn FV, et al. Renal tubular malfunction and pulmonary emphysema in cadmium pigment workers, Q. J Med 1963, 32:165-192.
274. Lande MB, Kim MS, et al. Reversible Fanconi syndrome associated with valproate therapy. J Pediatr 1993, 123(2):320-322.
275. Yang SS, Chu P, et al. Aristolochic acid-induced Fanconi's syndrome and nephropathy presenting as hypokalemic paralysis. Am J Kidney Dis 2002, 39(3):E14.
276. Lee S, Lee T, et al. Fanconi's syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid. Nephrology (Carlton) 2004, 9(3):126-129.
277. Hong YT, Fu LS, et al. Fanconi's syndrome, interstitial fibrosis and renal failure by aristolochic acid in Chinese herbs. Pediatr Nephrol 2006, 21(4):577-579.
278. Moss AH, Gabow PA, et al. Fanconi's syndrome and distal renal tubular acidosis after glue sniffing. Ann Intern Med 1980, 92(1):69-70.
279. Raschka C, Koch HJ Long-term treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage. Hum Exp Toxicol 1999, 18(12):738-739.
280. Rago RP, Miles JM, et al. Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans. Cancer 1994, 73(7):1954-1959.
281. Gil HW, Yang JO, et al. Paraquat-induced Fanconi syndrome. Nephrology (Carlton) 2005, 10(5):430-432.
282. Lo JC, Chertow GM, et al. Fanconi's syndrome and tubulointer-stitial nephritis in association with L-lysine ingestion. Am J Kidney Dis 1996, 28(4):614-617.
283. Igarashi T, Kawato H, et al. Acute tubulointerstitial nephritis with uveitis syndrome presenting as multiple tubular dysfunction including Fanconi's syndrome. Pediatr Nephrol 1992, 6(6):547-549.